PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan

MBX Biosciences, Inc (MBX) Sharpe Ratio: 2.32

Equity · Currency in USD · Last updated Jun 18, 2026

MBX Biosciences, Inc. focuses on the discovery and development of precision peptide therapies for endocrine and metabolic disorders, with lead candidates including MBX 2109 for chronic hypoparathyroidism, MBX 1416 for post-bariatric hypoglycemia, and MBX 4291 for obesity and related co-morbidities.

MBX's Sharpe Ratio of 2.32 indicates that for each unit of volatility, it generates 2.32 units of excess return above the risk-free rate. The ratio is calculated using historical daily returns over the past 12 months (as of Jun 18, 2026).

Sharpe uses total volatility (standard deviation) which includes both upside and downside price movements, making it useful for comparing risk-adjusted returns across different assets. For how to read this number and when it can mislead, see Sharpe Ratio Explained.

MBX Sharpe Ratio Rank

MBX Sharpe Ratio Rank: 91.692
Exceptional

MBX ranks above 91.6% of all investments in our database based on Sharpe Ratio over the past 12 months, demonstrating exceptional risk-adjusted returns. Securities are ranked from 0 (worst) to 100 (best).

What moves the rank

  • Strong returns with low total volatility → Higher rank
  • High volatility (both upside and downside) → Lower rank
  • Consistent returns → Higher rank than volatile returns of same magnitude
  • Sharp drawdowns increase volatility → Lower rank

What you can do with this information

  • Suitable as a core holding given strong risk-adjusted returns
  • Monitor rank changes to detect deteriorating return-to-volatility profile
  • Exceptional Sharpe ratio supports larger position sizes
  • Compare with category peers to assess whether strength is investment-specific or category-wide

MBX Sharpe Ratio Market Positioning

The chart shows MBX's Sharpe Ratio relative to all stocks on our platform, with color zones indicating percentile rankings. Higher ratios indicate better risk-adjusted returns.

  • Red zone (bottom 25%): -0.39 or lower
  • Yellow zone (middle 50%): -0.39 to 1.11
  • Green zone (top 25%): 1.11 or higher
  • Top 1%: 5.55+
  • Median: 0.22 — half of all investments score higher

How it compares to other similar stocks

The table compares MBX Biosciences, Inc's Sharpe Ratio with other stocks in the Biotechnology industry across multiple time periods, showing how MBX's risk-adjusted performance compares to industry peers.

Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Jun 18, 2026.

SymbolName1Y Sharpe Ratio5Y Sharpe Ratio10Y Sharpe RatioAll Time Sharpe Ratio
RVMDWRevolution Medicines Inc. Warrant11.49
SLGLSol-Gel Technologies Ltd.9.10
ERASErasca, Inc.8.97
CLYMClimb Bio Inc8.63
SYRESpyre Therapeutics Inc.7.11
ANROAlto Neuroscience, Inc6.90
RLMDRelmada Therapeutics, Inc.6.89
KODKodiak Sciences Inc.6.73
ORKAOruka Therapeutics, Inc6.56
ARWRArrowhead Pharmaceuticals, Inc.6.52
MBXMBX Biosciences, Inc2.32

S&P 500 Index

How to choose period

Historical Sharpe Ratio

The chart shows MBX's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.

Identify market cycles by observing when MBX consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.

Loading charts...

Sharpe Ratio Calculator

How does MBX fit in your portfolio?

Add your other holdings to see your portfolio's Sharpe Ratio and find out.

Analyze Your Portfolio